JP2017507973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507973A5 JP2017507973A5 JP2016556969A JP2016556969A JP2017507973A5 JP 2017507973 A5 JP2017507973 A5 JP 2017507973A5 JP 2016556969 A JP2016556969 A JP 2016556969A JP 2016556969 A JP2016556969 A JP 2016556969A JP 2017507973 A5 JP2017507973 A5 JP 2017507973A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- composition according
- carbidopa
- levodopa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 24
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 20
- 229960004205 carbidopa Drugs 0.000 claims 18
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 18
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 17
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 17
- 229960004502 levodopa Drugs 0.000 claims 17
- 239000004475 Arginine Substances 0.000 claims 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 235000010323 ascorbic acid Nutrition 0.000 claims 12
- 239000011668 ascorbic acid Substances 0.000 claims 12
- 229960005070 ascorbic acid Drugs 0.000 claims 12
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 10
- 235000013878 L-cysteine Nutrition 0.000 claims 10
- 239000004201 L-cysteine Substances 0.000 claims 10
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 10
- 229960004308 acetylcysteine Drugs 0.000 claims 10
- 229960002433 cysteine Drugs 0.000 claims 10
- 229960003194 meglumine Drugs 0.000 claims 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 8
- 229920000053 polysorbate 80 Polymers 0.000 claims 8
- 229940068968 polysorbate 80 Drugs 0.000 claims 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 235000010378 sodium ascorbate Nutrition 0.000 claims 6
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 6
- 229960005055 sodium ascorbate Drugs 0.000 claims 6
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 5
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 5
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 210000005064 dopaminergic neuron Anatomy 0.000 claims 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- RGWPPSAULBHMAA-NXEZZACHSA-N (2r)-2-amino-2-[[[(2r)-2-amino-2-carboxy-3-oxobutyl]disulfanyl]methyl]-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CSSC[C@@](N)(C(C)=O)C(O)=O RGWPPSAULBHMAA-NXEZZACHSA-N 0.000 claims 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 claims 1
- 239000004261 Ascorbyl stearate Substances 0.000 claims 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000004260 Potassium ascorbate Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019276 ascorbyl stearate Nutrition 0.000 claims 1
- 235000010376 calcium ascorbate Nutrition 0.000 claims 1
- 229940047036 calcium ascorbate Drugs 0.000 claims 1
- 239000011692 calcium ascorbate Substances 0.000 claims 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000019275 potassium ascorbate Nutrition 0.000 claims 1
- 229940017794 potassium ascorbate Drugs 0.000 claims 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952477P | 2014-03-13 | 2014-03-13 | |
| US61/952,477 | 2014-03-13 | ||
| US201461990967P | 2014-05-09 | 2014-05-09 | |
| US61/990,967 | 2014-05-09 | ||
| PCT/IL2015/050258 WO2015136538A1 (en) | 2014-03-13 | 2015-03-12 | Dopa decarboxylase inhibitor compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019170864A Division JP6770158B2 (ja) | 2014-03-13 | 2019-09-19 | ドーパデカルボキシラーゼ阻害剤組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507973A JP2017507973A (ja) | 2017-03-23 |
| JP2017507973A5 true JP2017507973A5 (enExample) | 2018-04-12 |
| JP6591995B2 JP6591995B2 (ja) | 2019-10-16 |
Family
ID=53488380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556969A Active JP6591995B2 (ja) | 2014-03-13 | 2015-03-12 | ドーパデカルボキシラーゼ阻害剤組成物 |
| JP2019170864A Active JP6770158B2 (ja) | 2014-03-13 | 2019-09-19 | ドーパデカルボキシラーゼ阻害剤組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019170864A Active JP6770158B2 (ja) | 2014-03-13 | 2019-09-19 | ドーパデカルボキシラーゼ阻害剤組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10022320B2 (enExample) |
| EP (3) | EP3116475B1 (enExample) |
| JP (2) | JP6591995B2 (enExample) |
| CN (1) | CN106413754B (enExample) |
| AU (1) | AU2015228369B2 (enExample) |
| BR (1) | BR112016021034A8 (enExample) |
| CA (1) | CA2942244C (enExample) |
| DK (2) | DK3116475T3 (enExample) |
| ES (2) | ES2836325T3 (enExample) |
| FI (1) | FI3777833T3 (enExample) |
| HR (2) | HRP20201948T1 (enExample) |
| HU (2) | HUE064818T2 (enExample) |
| IL (1) | IL247668B (enExample) |
| MX (1) | MX2016011837A (enExample) |
| PL (2) | PL3116475T3 (enExample) |
| PT (2) | PT3116475T (enExample) |
| RS (1) | RS65060B1 (enExample) |
| RU (1) | RU2684105C2 (enExample) |
| WO (1) | WO2015136538A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2559083C9 (ru) | 2009-05-19 | 2016-01-20 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| CN110123743A (zh) | 2010-11-15 | 2019-08-16 | 纽罗德姆有限公司 | L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| EP3116475B1 (en) | 2014-03-13 | 2020-11-04 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| JP6491747B2 (ja) | 2015-09-30 | 2019-03-27 | デューク・ユニヴァーシティ | 磁気共鳴画像法用の造影剤 |
| WO2018154447A1 (en) * | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| UY38473A (es) | 2018-11-15 | 2020-06-30 | Abbvie Inc | Formulaciones farmacéuticas para una administración subcutánea |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| CN113396897B (zh) * | 2021-07-26 | 2022-06-07 | 苏州华测生物技术有限公司 | 一种稳定生物基质中卡比多巴/左旋多巴的方法 |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| AU6889274A (en) | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| JPS56115749A (en) | 1980-02-18 | 1981-09-11 | Sagami Chem Res Center | Dopa derivative |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| ES2042520T3 (es) | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
| US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| IT1226902B (it) | 1988-07-12 | 1991-02-21 | Mini Ricerca Scient Tecnolog | Processo per la sintesi del levodopa |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5350769A (en) | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2143070C (en) | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| ES2211904T3 (es) | 1995-05-26 | 2004-07-16 | Pfizer Inc. | Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda. |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| US6746688B1 (en) | 1996-10-13 | 2004-06-08 | Neuroderm Ltd. | Apparatus for the transdermal treatment of Parkinson's disease |
| IL119417A (en) | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US6245917B1 (en) | 1998-03-20 | 2001-06-12 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| IL139298A0 (en) | 1998-05-15 | 2001-11-25 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| EP1345925B1 (en) | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| IL159812A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
| BRPI0213425B8 (pt) | 2001-10-19 | 2021-05-25 | Idexx Lab Inc | composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| ES2189682B1 (es) | 2001-12-11 | 2004-04-01 | Laboratorios Del Dr. Esteve, S.A. | Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea. |
| WO2003084514A1 (en) | 2002-04-11 | 2003-10-16 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of carbidopa and levodopa |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| EP1551829B1 (de) | 2002-10-10 | 2010-04-07 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Neue verbindungen mit antibakterieller aktivität |
| EP1596808A4 (en) | 2003-02-07 | 2007-04-04 | Yissum Res Dev Co | L-DOPA AMID DERIVATIVES AND THEIR USE |
| WO2005035088A2 (en) | 2003-07-18 | 2005-04-21 | Baxter International, Inc. | Method for preparing small spherical by controlled phase separation |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| JP5160786B2 (ja) * | 2003-08-29 | 2013-03-13 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物及びレボドパ及びカルビドパの使用方法 |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| WO2005041925A2 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2006037061A2 (en) | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| CA2582346A1 (en) | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| ATE444746T1 (de) | 2005-06-08 | 2009-10-15 | Orion Corp | Eine herstellungsmethode von entacapon- enthaltenden granulaten für orale dosierformen |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| RU2484815C2 (ru) | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| PE20080669A1 (es) | 2006-09-08 | 2008-07-18 | Drugtech Corp | Composicion de liberacion sostenida que comprende levodopa |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| EP2144663A4 (en) | 2007-04-06 | 2011-06-22 | Transform Pharmaceuticals Inc | SYSTEMS AND METHODS FOR DISTRIBUTING A FLUID MEDICINE |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| AU2009211028B2 (en) * | 2008-02-06 | 2013-12-05 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| WO2010055133A1 (en) | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| RU2559083C9 (ru) * | 2009-05-19 | 2016-01-20 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| SI2640370T1 (en) | 2010-11-15 | 2018-08-31 | Neuroderm Ltd Weizmann Science Park | Compounds for transdermal delivery of active ingredients |
| CN110123743A (zh) | 2010-11-15 | 2019-08-16 | 纽罗德姆有限公司 | L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用 |
| BR112013014304A2 (pt) | 2010-12-10 | 2016-07-19 | Synagile Corp | composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| TR201204839A2 (tr) * | 2012-04-25 | 2012-12-21 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu. |
| WO2013184646A2 (en) | 2012-06-05 | 2013-12-12 | Synagile Corporation | Dosing regimens for subcutaneously infusible acidic compositions |
| WO2013183055A1 (en) | 2012-06-05 | 2013-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| RU2677278C2 (ru) * | 2013-03-13 | 2019-01-16 | Неуродерм Лтд | Способ лечения болезни паркинсона |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| EP3116475B1 (en) | 2014-03-13 | 2020-11-04 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| MX393568B (es) | 2014-10-21 | 2025-03-24 | Abbvie Inc | Profarmacos de carbidopa y l-dopa y metodos de uso |
| RU2018119194A (ru) | 2015-11-24 | 2019-12-25 | Нейродерм Лтд. | Фармацевтические композиции, содержащие амид леводопы, и их применения |
| WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| WO2019038638A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA |
| AR112683A1 (es) | 2017-08-21 | 2019-11-27 | Neuroderm Ltd | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende |
| WO2019038637A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM |
-
2015
- 2015-03-12 EP EP15731727.2A patent/EP3116475B1/en active Active
- 2015-03-12 MX MX2016011837A patent/MX2016011837A/es active IP Right Grant
- 2015-03-12 HR HRP20201948TT patent/HRP20201948T1/hr unknown
- 2015-03-12 EP EP20198371.5A patent/EP3777833B1/en active Active
- 2015-03-12 PT PT157317272T patent/PT3116475T/pt unknown
- 2015-03-12 HU HUE20198371A patent/HUE064818T2/hu unknown
- 2015-03-12 RS RS20240006A patent/RS65060B1/sr unknown
- 2015-03-12 BR BR112016021034A patent/BR112016021034A8/pt not_active Application Discontinuation
- 2015-03-12 PL PL15731727T patent/PL3116475T3/pl unknown
- 2015-03-12 FI FIEP20198371.5T patent/FI3777833T3/fi active
- 2015-03-12 AU AU2015228369A patent/AU2015228369B2/en active Active
- 2015-03-12 PT PT201983715T patent/PT3777833T/pt unknown
- 2015-03-12 DK DK15731727.2T patent/DK3116475T3/da active
- 2015-03-12 JP JP2016556969A patent/JP6591995B2/ja active Active
- 2015-03-12 CN CN201580024073.7A patent/CN106413754B/zh active Active
- 2015-03-12 US US14/645,848 patent/US10022320B2/en active Active
- 2015-03-12 HR HRP20231716TT patent/HRP20231716T1/hr unknown
- 2015-03-12 EP EP23204007.1A patent/EP4299128A3/en not_active Withdrawn
- 2015-03-12 WO PCT/IL2015/050258 patent/WO2015136538A1/en not_active Ceased
- 2015-03-12 CA CA2942244A patent/CA2942244C/en active Active
- 2015-03-12 HU HUE15731727A patent/HUE052642T2/hu unknown
- 2015-03-12 ES ES15731727T patent/ES2836325T3/es active Active
- 2015-03-12 ES ES20198371T patent/ES2967693T3/es active Active
- 2015-03-12 RU RU2016135952A patent/RU2684105C2/ru active
- 2015-03-12 DK DK20198371.5T patent/DK3777833T3/da active
- 2015-03-12 PL PL20198371.5T patent/PL3777833T3/pl unknown
-
2016
- 2016-09-06 IL IL247668A patent/IL247668B/en active IP Right Grant
-
2018
- 2018-06-14 US US16/008,228 patent/US10624839B2/en active Active
-
2019
- 2019-09-19 JP JP2019170864A patent/JP6770158B2/ja active Active
-
2020
- 2020-03-16 US US16/819,740 patent/US20210038505A1/en not_active Abandoned
-
2022
- 2022-09-01 US US17/901,078 patent/US20230240980A1/en not_active Abandoned
-
2025
- 2025-05-21 US US19/214,470 patent/US20260102334A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| HRP20200366T1 (hr) | Kontinuirana primjena l-dopa, inhibitora dopa-dekarboksilaze, inhibitora katekol-o-metil-transferaze i njihovih pripravaka | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| JP2013545745A5 (enExample) | ||
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| JP2011116787A5 (enExample) | ||
| AR067701A1 (es) | Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 | |
| PH12012502319A1 (en) | Soluble guanylate cyclase activators | |
| EP4663637A3 (en) | Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2015510888A5 (enExample) | ||
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MY173867A (en) | Process to minimize polymorphism | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2017514924A5 (enExample) | ||
| SA521422467B1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| MX2019003470A (es) | Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. | |
| ZA201906327B (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| MX2026001663A (es) | Formulaciones farmaceuticas de agonistas de gpr119 y usos de estas | |
| AR075097A1 (es) | Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia | |
| FI4000628T3 (fi) | Koostumus ja menetelmä vankomysiinin oraaliselle nesteelle | |
| JP2017008001A5 (enExample) |